Comparison of platelet aggregation evaluated by Multiplate-TRAP after 10 ± 2 days of edoxaban and clopidogrel versus clopidogrel alone in patients with coronary artery disease.

• Grant number: 24/16405-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2024
• End date: September 30, 2025
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: José Carlos Nicolau
• Grantee: Rodrigo do Nascimento Marano Carneiro
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated research grant: 23/10447-4 - Platelet aggregation: new therapeutic interventions, mechanisms and evaluation methods, with focus on high social impact diseases, AP.TEM

Abstract

Antiplatelet therapy plays a fundamental role in preventing thromboembolic events in patients with coronary artery disease (CAD). Clopidogrel is commonly used as an antiplatelet agent. Edoxaban, a direct-acting oral anticoagulant, has demonstrated efficacy in reducing thromboembolic events in various clinical contexts. However, it remains unclear whether the addition of edoxaban to clopidogrel therapy can result in greater inhibition of platelet aggregation in patients with CAD.